Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pegasys

- PMLiVE

Glimmer of hope for amyloid drugs in Alzheimer’s?

Expectations remain high but high efficacy rates still allusive for most firms

- PMLiVE

Anti-hypertensive market to slow in Asia-Pacific

New data shows the value will approach $20bn 2021

Roche Basel Switzerland

Roche’s breakthrough PD-L1 drug slows cancer growth

Latest positive trial for the firm’s next-gen oncology product atezolizumab

- PMLiVE

Paradigm Comms and Trio Health win healthcare media relations award

Judges said the campaign was a true ‘vehicle for action and change’

- PMLiVE

Roche and Evotec’s Alzheimer’s drug ineffective

Sembragiline failed to show cognitive and memory benefits

Roche Basel Switzerland

Roche planning ocrelizumab filings in early 2016

Firm claims MS candidate outperformed Merck Serono’s Rebif in two phase III trials

- PMLiVE

BMS drops antiviral research in R&D shake-up

Up to 100 positions set to be lost by the US company’s research shift

China flag thumb

China turns down one of two Sovaldi patents

Advocacy group attempting to block drug in other emerging markets too

- PMLiVE

Generic Copaxone launches in US

Sandoz and Momenta Pharmaceuticals started shipping Glatopa in reaction

- PMLiVE

NHS England sets up new £190m hep C fund

Will see patients gain access to treatments from Gilead and AbbVie

ABPI London offices

UK pharma rebate payment doubles in one year

First quarter repayment £138m higher than this time last year

Gilead Sciences

Humira remains top pharma product, but Sovaldi closes in

AbbVie’s blockbuster may be bumped to second place this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links